Skin Seed Amplification Assay differentiates Multiple System Atrophy from Parkinson’s Disease
Preprint
Abstract
Background: Misdiagnoses of multiple system atrophy (MSA) and Parkinson’s disease (PD) remain common due to overlapping clinical features. Objective: To develop and assess a skin α-synuclein seed amplification assay (αSyn-SAA) for detecting pathological α-synuclein and distinguishing MSA from PD. Methods: In this blinded, cross-sectional study conducted across two laboratories, 308 skin biopsies from 117 participants were analyzed using a standardized αSyn-SAA protocol. The cohort included 42 PD, 31 MSA, 30 controls, and 14 with progressive supranuclear palsy (PSP). Biopsies were obtained from up to four anatomical sites and positivity was defined as ≥75% positive replicates. Kinetic parameters were analyzed to differentiate PD and MSA, and clinical features were correlated with αSyn-SAA positivity. Fibril morphology from amplified skin samples was compared to postmortem brain using proteinase K digestion and electron microscopy. Results: αSyn-SAA detected synucleinopathy in 86% of PD and 77% of MSA patients, with 90% specificity versus controls and 86% versus PSP. ROC analysis showed that maximum fluorescence (Fmax, AUC = 0.93) and lag time (AUC = 0.91) distinguished PD from MSA at the biopsy level. A 50% mean Fmax cutoff across positive samples accurately differentiated synucleinopathies with 90% sensitivity and 85% specificity. αSyn-SAA positivity correlated with RBD in both disorders and with autonomic features in MSA. Amplified fibrils displayed distinct structural and proteolytic profiles between PD and MSA, consistent with brain-derived aggregates. Conclusion: Skin αSyn-SAA detects pathological α-synuclein in living patients with high accuracy and distinguishes MSA from PD based on assay kinetics and fibril strain properties.Keywords
This publication has 44 references indexed in Scilit:
- High rates of diagnostic discordance and co‐pathology: Insights into PSP from the NACC datasetAlzheimer's & Dementia, 2025
- Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With SynucleinopathiesJAMA, 2024
- α‐Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies Using Cerebrospinal Fluid—A Systematic Review and Meta‐AnalysisMovement Disorders Clinical Practice, 2023
- Update of the MDS research criteria for prodromal Parkinson's diseaseMovement Disorders, 2019
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteriaMovement Disorders, 2017
- Skin nerve misfolded α‐synuclein in pure autonomic failure and Parkinson diseaseAnnals of Neurology, 2015
- MDS clinical diagnostic criteria for Parkinson's diseaseMovement Disorders, 2015
- Distinctive distribution of phospho-alpha-synuclein in dermal nerves in multiple system atrophyMovement Disorders, 2015
- A single‐question screen for rapid eye movement sleep behavior disorder: A multicenter validation studyMovement Disorders, 2012
- International multicenter pilot study of the first comprehensive self‐completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest studyMovement Disorders, 2006